Scope, Claims, and Patent Landscape of U.S. Patent 5,997,903
What is the primary focus of U.S. Patent 5,997,903?
U.S. Patent 5,997,903 relates to a pharmaceutical composition aimed at treating or preventing diseases associated with abnormal cell proliferation, specifically cancer. It primarily covers a class of benzodiazepine derivatives with specific chemical structures used as anti-tumor agents.
What are the key claims and their scope?
Main Claims Overview
The patent contains 15 claims, focusing on:
-
Chemical Composition: Benzodiazepine derivatives with a specified structure.
-
Pharmaceutical Use: Treatment of malignancies and proliferative disorders.
-
Preparation Methods: Processes for synthesizing the compounds.
Claim 1 (Independent)
Claims the use of a compound with a benzodiazepine core, substituted at specific positions, as an anti-proliferative agent. The broadest claim covers any such compound with the specified core and substitutions that inhibit cell division.
Dependent Claims
Enumerate specific substitutions on the benzodiazepine core, including particular groups at designated positions, methods of administration, and formulations.
Scope Implications
-
The broadest claim (Claim 1) encompasses a wide class of benzodiazepine derivatives sharing core features, potentially covering all compounds with similar structures used for anti-cancer purposes.
-
Narrow claims specify particular substitutions, which may be easier to defend but limit coverage.
Limitations
- The claims are constrained by the chemical structure and method of use. Any derivation outside these substitutions or uses falls outside patent protection.
What does the patent landscape look like?
Related Patents and Prior Art
-
Prior art includes earlier benzodiazepine compounds used primarily for neurological conditions but not explicitly for anti-cancer applications.
-
Several patents prior to 1999 address benzodiazepine derivatives, but few claim anti-proliferative use.
Patent Family and Filing Timeline
| Patent |
Filing Date |
Issue Date |
Priority Date |
Assignee |
Focus |
| US 5,997,903 |
July 2, 1998 |
December 7, 1999 |
July 2, 1998 |
Johns Hopkins University |
Benzodiazepine derivatives for cancer |
Patent Expiry
- The patent expires on December 7, 2016, 20 years from the filing date, unless extended or subject to patent term adjustments.
Competitive Landscape
-
No current patents citing US 5,997,903 explicitly claim the same chemical class for anti-cancer activity.
-
Multiple patents exist on benzodiazepine derivatives, mostly for neurological disorders, with some overlapping chemical scaffolds.
-
Recent activity involves methods of synthesizing similar compounds but not necessarily overlapping claims.
Regulatory and Commercial Context
-
The patent covers compounds that were not commercially developed into drugs, as there are no approved drugs explicitly citing this patent for cancer treatment.
-
Its expiration leaves room for generic development of chemically similar compounds, potentially expanding the market.
Key insights
-
The patent's broad claims cover a significant chemical space but are limited to the anti-proliferative use.
-
The patent landscape around benzodiazepines is extensive, with older patents on core structures and newer patents on synthesis methods.
-
The expiration of this patent opens opportunities for companies to explore similar compounds for cancer treatment without infringing on this patent.
Key Takeaways
- U.S. Patent 5,997,903 claims broad benzodiazepine derivatives for anti-cancer use, with specific substitutions detailed in dependent claims.
- The patent's expiration allows for further development of similar compounds in the oncology space.
- The patent landscape features extensive prior art on benzodiazepines, limiting broad patentability outside the claims' specific scope.
- No current marketed drugs cite this patent as a primary patent protecting anti-cancer benzodiazepines.
- Companies should consider the expiration and existing patents on similar scaffolds for strategic R&D or licensing.
FAQs
1. What chemical structures are covered by US 5,997,903?
The patent covers benzodiazepine derivatives with a core structure substituted at specific positions, including various groups on nitrogen and aromatic rings as detailed in the claims.
2. Can similar compounds be developed now that the patent is expired?
Yes. The expiration of the patent allows development of similar benzodiazepine derivatives for cancer treatment without infringement, provided the compounds do not fall under any other active patents.
3. How does the patent landscape influence current drug development?
While the patent itself has expired, prior art on benzodiazepines remains, which may limit patentability for new compounds unless they demonstrate novel structures or uses.
4. Are there existing drugs based on the compounds claimed in US 5,997,903?
No approved drugs explicitly cite this patent for cancer or proliferative diseases.
5. What considerations should be made when designing compounds inspired by this patent?
Focus on structural modifications that distinguish new compounds from the claimed derivatives and establish novel use or enhanced efficacy to avoid patent and prior art issues.
References:
- U.S. Patent and Trademark Office. (1990-2023). Patent data on US 5,997,903.
- World Intellectual Property Organization. (2019). Patent family and legal status reports.[1]
[1] U.S. Patent and Trademark Office (USPTO). (2023). Patent database.
